Press Releases
October 28, 2014
Gilead Sciences Announces Third Quarter 2014 Financial Results
- Product Sales of
- Sovaldi Sales of
- Non-GAAP EPS of
- Revised 2014 Full Year Guidance -
“To date approximately 117,000 patients have been treated with Sovaldi
and with the introduction of Harvoni - a single tablet regimen for the
treatment of HCV-infected individuals which does not require either
interferon or ribavirin - many more patients will have the potential to
be cured of HCV infection,” said
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| (In thousands, except per share amounts) | 2014 | 2013 | 2014 | 2013 | |||||||||||
| Product sales | $ | 5,968,208 | $ | 2,709,652 | $ | 17,252,119 | $ | 7,760,505 | |||||||
| Royalty, contract and other revenues | 73,624 | 73,181 | 323,612 | 321,357 | |||||||||||
| Total revenues | $ | 6,041,832 | $ | 2,782,833 | $ | 17,575,731 | $ | 8,081,862 | |||||||
| Net income attributable to Gilead | $ | 2,731,274 | $ | 788,606 | $ | 8,614,277 | $ | 2,283,397 | |||||||
| Non-GAAP net income attributable to Gilead | $ | 3,013,691 | $ | 879,081 | $ | 9,431,033 | $ | 2,520,749 | |||||||
| Diluted EPS | $ | 1.67 | $ | 0.47 | $ | 5.18 | $ | 1.35 | |||||||
| Non-GAAP diluted EPS | $ | 1.84 | $ | 0.52 | $ | 5.68 | $ | 1.49 | |||||||
Product Sales
U.S. product sales for the third quarter of 2014 increased to
Antiviral Product Sales
Antiviral product sales increased to
| Three Months Ended | Nine Months Ended | |||||||||||||||||||
| September 30, | September 30, | |||||||||||||||||||
| (In thousands, except percentages) | 2014 | 2013 | % Change | 2014 | 2013 | % Change | ||||||||||||||
| Antiviral product sales | $ | 5,544,513 | $ | 2,326,727 | 138% | $ | 16,065,154 | $ | 6,701,344 | 140% | ||||||||||
| Sovaldi | 2,796,093 | — | —% | 8,550,768 | — | —% | ||||||||||||||
| Atripla | 894,787 | 899,669 | (1)% | 2,545,089 | 2,714,850 | (6)% | ||||||||||||||
| Truvada | 875,454 | 813,652 | 8% | 2,441,764 | 2,321,673 | 5% | ||||||||||||||
| Complera/Eviplera | 330,263 | 210,736 | 57% | 880,460 | 547,608 | 61% | ||||||||||||||
| Stribild | 328,035 | 143,953 | 128% | 812,826 | 335,495 | 142% | ||||||||||||||
| Viread | 275,637 | 231,555 | 19% | 746,996 | 692,075 | 8% | ||||||||||||||
Cardiovascular Product Sales
Cardiovascular product sales increased to
| Three Months Ended | Nine Months Ended | |||||||||||||||||||
| September 30, | September 30, | |||||||||||||||||||
| (In thousands, except percentages) | 2014 | 2013 | % Change | 2014 | 2013 | % Change | ||||||||||||||
| Cardiovascular product sales | $ | 278,925 | $ | 250,887 | 11% | $ | 780,100 | $ | 700,134 | 11% | ||||||||||
| Letairis | 146,415 | 135,072 | 8% | 414,016 | 381,436 | 9% | ||||||||||||||
| Ranexa | 132,510 | 115,815 | 14% | 366,084 | 318,698 | 15% | ||||||||||||||
Operating Expenses
During the third quarter of 2014, compared to the same period in 2013:
- Non-GAAP research and development (R&D) expenses increased primarily due to the progression and expansion of our clinical studies.
-
Non-GAAP selling, general and administrative (SG&A) expenses increased
primarily due to a cumulative catch-up of
$337 million ($0.21 per diluted share) related to the non-tax deductible BPD fee for final regulations in the Affordable Care Act issued during the quarter. SG&A expense increases also reflect costs to support our business expansion related primarily to Sovaldi and Zydelig® (idelalisib 150 mg).
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| (In thousands) | 2014 | 2013 | 2014 | 2013 | |||||||||||
| Non-GAAP research and development expenses | $ | 586,325 | $ | 488,535 | $ | 1,686,104 | $ | 1,436,282 | |||||||
| Non-GAAP selling, general and administrative expenses | $ | 888,251 | $ | 376,841 | $ | 1,957,586 | $ | 1,086,241 | |||||||
|
Note: |
Non-GAAP R&D and SG&A expenses exclude the impact of acquisition-related, restructuring and stock-based compensation expenses. |
|
Cash,
As of
Revised 2014 Full Year Guidance
Gilead updated its full year 2014 guidance, which it initially provided
on
| (In millions, except percentages and per share amounts) |
Initially Provided |
Updated |
Provided on |
|||
| Net Product Sales | $11,300 - $11,500 | $21,000 - $23,000 | $22,000 - $23,000 | |||
| Non-GAAP* | ||||||
| Product Gross Margin | 75% - 77% | 85% - 88% | 86% - 88% | |||
| R&D | $2,200 - $2,300 | $2,300 - $2,400 | $2,300 - $2,400 | |||
| SG&A | $2,100 - $2,200 | $2,300 - $2,400 | $2,700 - $2,800 ** | |||
| Effective Tax Rate | 28% - 29% | 17.5% - 20.5% | 17.5% - 19.5% | |||
| Diluted EPS Impact of Acquisition-Related, Restructuring and Stock-Based Compensation Expenses | $0.63 - $0.66 | $0.63 - $0.66 | $0.63 - $0.66 | |||
| * Non-GAAP product gross margin, expenses and effective tax rate exclude the impact of acquisition-related, restructuring and stock-based compensation expenses, where applicable. | ||||||
| ** Includes the impact of the Internal Revenue Service regulations related to the change in accounting of the branded prescription drug fee, which is estimated at approximately $400 million. | ||||||
Product & Pipeline Updates Announced by
Antiviral Program
-
Announced that the
Committee for Medicinal Products for Human Use , the scientific committee of theEuropean Medicines Agency , adopted a positive opinion on Gilead's Marketing Authorization Application for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg). - Announced topline results from two Phase 3 clinical trials (Studies 104 and 111), which demonstrated that an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives. The studies demonstrated that the single tablet regimen (E/C/F/TAF) comprising elvitegravir, cobicistat, emtricitabine and TAF, was non-inferior to Gilead's Stribild (elvitegravir /cobicistat /emtricitabine /tenofovir disoproxil fumarate) based on the proportion of patients with HIV RNA levels (viral load) of less than 50 copies/mL at 48 weeks of therapy. In addition, E/C/F/TAF demonstrated more favorable renal and bone safety compared to Stribild.
-
Submitted a New Drug Application (NDA) to
Japan's Pharmaceutical and Medical Devices Agency for approval of a once-daily fixed-dose combination of ledipasvir (LDV) 90 mg and sofosbuvir (SOF) 400 mg for the treatment of chronic genotype 1 HCV infection in adults. If approved, LDV/SOF would simplify HCV treatment for genotype 1 patients inJapan to one daily tablet, eliminating the need for interferon and ribavirin. -
Announced that Gilead has signed non-exclusive licensing agreements
with seven
India -based generic pharmaceutical manufacturers to expand access to its chronic HCV medicines in developing countries. The agreements allow the companies to manufacture SOF and the single tablet regimen of LDV/SOF for distribution in 91 developing countries. -
Announced a new agreement with the
Medicines Patent Pool (MPP) to expand access to TAF for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval. Under the agreement, the MPP can sub-license TAF to generic drug companies inIndia andChina , who may manufacture and distribute it in 112 developing countries.
Oncology Program
-
Received U.S. Food and Drug Administration approval for Zydelig for the treatment of three B-cell blood cancers. Zydelig is indicated in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy and as monotherapy for patients with relapsed follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies. -
The European Commission granted marketing authorization for Zydelig for CLL and FL. For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. For the treatment of FL, Zydelig has been approved as a monotherapy in patients who are refractory to two prior lines of treatment.
Cardiovascular Program
-
Announced positive results from the AMBITION study (a randomized,
double-blind, multicenter study of first-line combination therapy with AMBrIsentan
and Tadalafil in patients with pulmonary arterial hypertensION),
which was conducted in collaboration with
GlaxoSmithKline plc . In AMBITION, first-line treatment of pulmonary arterial hypertension with the combination of ambrisentan 10 mg and tadalafil 40 mg reduced the risk of clinical failure by 50 percent compared to the pooled ambrisentan and tadalafil monotherapy arm. The combination was also statistically significant versus the individual ambrisentan and tadalafil monotherapy groups for the primary endpoint.
Conference Call
At
A replay of the webcast will be archived on the company's website for
one year, and a phone replay will be available approximately two hours
following the call through
About Gilead
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (GAAP) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on pages 7 and 8.
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead's ability to achieve its
anticipated full year 2014 financial results; Gilead's ability to
sustain growth in revenues for its antiviral, cardiovascular and
respiratory programs; availability of funding for state AIDS Drug
Assistance Programs (ADAPs); continued fluctuations in ADAP purchases
driven by federal and state grant cycles which may not mirror patient
demand and may cause fluctuations in Gilead's earnings; the possibility
of unfavorable results from clinical trials involving TAF, including in
combination with other products; Gilead's ability to initiate clinical
trials in its currently anticipated timeframes; the levels of inventory
held by wholesalers and retailers which may cause fluctuations in
Gilead's earnings; Gilead's ability to submit NDAs for new product
candidates in the timelines currently anticipated; Gilead's ability to
receive regulatory approvals in a timely manner or at all, for new and
current products, including SOF and the fixed-dose combination of
LDV/SOF in
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead owns or has rights to various trademarks, copyrights and trade
names used in our business, including the following: GILEAD®,
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb &
For more information on
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in thousands, except per share amounts) |
||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2014 | 2013 |
2014 |
2013 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 5,968,208 | $ | 2,709,652 | $ | 17,252,119 | $ | 7,760,505 | ||||||||
| Royalty, contract and other revenues | 73,624 | 73,181 | 323,612 | 321,357 | ||||||||||||
| Total revenues | 6,041,832 | 2,782,833 | 17,575,731 | 8,081,862 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 987,306 | 681,868 | 2,725,220 | 2,000,979 | ||||||||||||
| Research and development | 630,466 | 546,244 | 1,809,368 | 1,567,778 | ||||||||||||
| Selling, general and administrative | 944,837 | 406,860 | 2,106,515 | 1,186,147 | ||||||||||||
| Total costs and expenses | 2,562,609 | 1,634,972 | 6,641,103 | 4,754,904 | ||||||||||||
| Income from operations | 3,479,223 | 1,147,861 | 10,934,628 | 3,326,958 | ||||||||||||
| Interest expense | (103,366 | ) | (73,949 | ) | (281,639 | ) | (233,744 | ) | ||||||||
| Other income (expense), net | (5,037 | ) | 5,777 | (26,594 | ) | 2,222 | ||||||||||
| Income before provision for income taxes | 3,370,820 | 1,079,689 | 10,626,395 | 3,095,436 | ||||||||||||
| Provision for income taxes | 646,557 | 294,473 | 2,029,060 | 824,892 | ||||||||||||
| Net income | 2,724,263 | 785,216 | 8,597,335 | 2,270,544 | ||||||||||||
| Net loss attributable to noncontrolling interest | 7,011 | 3,390 | 16,942 | 12,853 | ||||||||||||
| Net income attributable to Gilead | $ | 2,731,274 | $ | 788,606 | $ | 8,614,277 | $ | 2,283,397 | ||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 1.80 | $ | 0.51 | $ | 5.64 | $ | 1.50 | ||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 1.67 | $ | 0.47 | $ | 5.18 | $ | 1.35 | ||||||||
| Shares used in per share calculation - basic | 1,513,899 | 1,532,105 | 1,527,633 | 1,526,847 | ||||||||||||
| Shares used in per share calculation - diluted | 1,636,530 | 1,691,898 | 1,662,281 | 1,689,647 | ||||||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in thousands, except percentages and per share amounts) |
||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 987,306 | $ | 681,868 | $ | 2,725,220 | $ | 2,000,979 | ||||||||
| Stock-based compensation expenses | (2,726 | ) | (1,823 | ) | (7,933 | ) | (6,296 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (201,490 | ) | (21,264 | ) | (599,950 | ) | (63,792 | ) | ||||||||
| Non-GAAP cost of goods sold | $ | 783,090 | $ | 658,781 | $ | 2,117,337 | $ | 1,930,891 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 83.5 | % | 74.8 | % | 84.2 | % | 74.2 | % | ||||||||
| Stock-based compensation expenses | 0.0 | % | 0.1 | % | 0.0 | % | 0.1 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 3.4 | % | 0.8 | % | 3.5 | % | 0.8 | % | ||||||||
| Non-GAAP product gross margin(1) | 86.9 | % | 75.7 | % | 87.7 | % | 75.1 | % | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 630,466 | $ | 546,244 | $ | 1,809,368 | $ | 1,567,778 | ||||||||
| Stock-based compensation expenses | (40,312 | ) | (27,740 | ) | (111,295 | ) | (79,261 | ) | ||||||||
| Restructuring expenses | (43 | ) | 31 | (217 | ) | (4,793 | ) | |||||||||
| Acquisition related-contingent consideration remeasurement | (3,786 | ) | (30,000 | ) | (11,752 | ) | (47,442 | ) | ||||||||
| Non-GAAP research and development expenses | $ | 586,325 | $ | 488,535 | $ | 1,686,104 | $ | 1,436,282 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 944,837 | $ | 406,860 | $ | 2,106,515 | $ | 1,186,147 | ||||||||
| Stock-based compensation expenses | (56,298 | ) | (33,010 | ) | (145,466 | ) | (94,736 | ) | ||||||||
| Restructuring expenses | (3 | ) | 2,972 | (8 | ) | 2,534 | ||||||||||
| Acquisition related-transaction costs | (4 | ) | 300 | (559 | ) | (6,860 | ) | |||||||||
| Acquisition related-amortization of purchased intangibles | (281 | ) | (281 | ) | (2,896 | ) | (844 | ) | ||||||||
| Non-GAAP selling, general and administrative expenses | $ | 888,251 | $ | 376,841 | $ | 1,957,586 | $ | 1,086,241 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 57.6 | % | 41.2 | % | 62.2 | % | 41.2 | % | ||||||||
| Stock-based compensation expenses | 1.6 | % | 2.2 | % | 1.5 | % | 2.2 | % | ||||||||
| Restructuring expenses | 0.0 | % | (0.1 | )% | 0.0 | % | 0.0 | % | ||||||||
| Acquisition related-transaction costs | 0.0 | % | 0.0 | % | 0.0 | % | 0.1 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 3.3 | % | 0.8 | % | 3.4 | % | 0.8 | % | ||||||||
| Acquisition related-contingent consideration remeasurement | 0.1 | % | 1.1 | % | 0.1 | % | 0.6 | % | ||||||||
| Non-GAAP operating margin(1) | 62.6 | % | 45.2 | % | 67.2 | % | 44.9 | % | ||||||||
| Other income (expense) reconciliation: | ||||||||||||||||
| GAAP other income (expense), net | $ | (5,037 | ) | $ | 5,777 | $ | (26,594 | ) | $ | 2,222 | ||||||
| Acquisition related-transaction costs | — | — | (1,851 | ) | — | |||||||||||
| Non-GAAP other income (expense), net | $ | (5,037 | ) | $ | 5,777 | $ | (28,445 | ) | $ | 2,222 | ||||||
| (1) Amounts may not sum due to rounding. | ||||||||||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) (in thousands, except percentages and per share amounts) |
||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Effective tax rate reconciliation: | ||||||||||||||||
| GAAP effective tax rate | 19.2 | % | 27.3 | % | 19.1 | % | 26.6 | % | ||||||||
| Restructuring expenses | 0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | (1.0 | )% | 0.0 | % | (0.9 | )% | 0.0 | % | ||||||||
| Acquisition related-contingent consideration remeasurement | 0.0 | % | (0.9 | )% | 0.0 | % | (0.4 | )% | ||||||||
| Non-GAAP effective tax rate(1) | 18.2 | % | 26.4 | % | 18.2 | % | 26.2 | % | ||||||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead, net of tax | $ | 2,731,274 | $ | 788,606 | $ | 8,614,277 | $ | 2,283,397 | ||||||||
| Stock-based compensation expenses | 81,261 | 46,576 | 216,596 | 132,335 | ||||||||||||
| Restructuring expenses | 45 | (2,076 | ) | 218 | 3,048 | |||||||||||
| Acquisition related-transaction costs | (90 | ) | (300 | ) | (956 | ) | 6,860 | |||||||||
| Acquisition related-amortization of purchased intangibles | 197,415 | 16,275 | 589,146 | 47,667 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 3,786 | 30,000 | 11,752 | 47,442 | ||||||||||||
| Non-GAAP net income attributable to Gilead, net of tax | $ | 3,013,691 | $ | 879,081 | $ | 9,431,033 | $ | 2,520,749 | ||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
| GAAP diluted earnings per share | $ | 1.67 | $ | 0.47 | $ | 5.18 | $ | 1.35 | ||||||||
| Stock-based compensation expenses | 0.05 | 0.03 | 0.13 | 0.08 | ||||||||||||
| Restructuring expenses | 0.00 | (0.00 | ) | 0.00 | 0.00 | |||||||||||
| Acquisition related-transaction costs | (0.00 | ) | (0.00 | ) | (0.00 | ) | 0.00 | |||||||||
| Acquisition related-amortization of purchased intangibles | 0.12 | 0.01 | 0.35 | 0.03 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 0.00 | 0.02 | 0.01 | 0.03 | ||||||||||||
| Non-GAAP diluted earnings per share(1) | $ | 1.84 | $ | 0.52 | $ | 5.68 | $ | 1.49 | ||||||||
| Shares used in per share calculation (diluted) reconciliation: | ||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 1,636,530 | 1,691,898 | 1,662,281 | 1,689,647 | ||||||||||||
| Share impact of current stock-based compensation rules | (620 | ) | (1,139 | ) | (837 | ) | (1,281 | ) | ||||||||
| Non-GAAP shares used in per share calculation (diluted) | 1,635,910 | 1,690,759 | 1,661,444 | 1,688,366 | ||||||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 204,216 | $ | 23,087 | $ | 607,883 | $ | 70,088 | ||||||||
| Research and development expenses adjustments | 44,141 | 57,709 | 123,264 | 131,496 | ||||||||||||
| Selling, general and administrative expenses adjustments | 56,586 | 30,019 | 148,929 | 99,906 | ||||||||||||
| Other income (expense) adjustments | — | — | (1,851 | ) | — | |||||||||||
| Total non-GAAP adjustments before tax | 304,943 | 110,815 | 878,225 | 301,490 | ||||||||||||
| Income tax effect | (22,526 | ) | (20,340 | ) | (61,469 | ) | (64,138 | ) | ||||||||
| Total non-GAAP adjustments after tax | $ | 282,417 | $ | 90,475 | $ | 816,756 | $ | 237,352 | ||||||||
| (1) Amounts may not sum due to rounding. | ||||||||||||||||
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
|||||||
| September 30, | December 31, | ||||||
| 2014 | 2013(1) | ||||||
| (unaudited) | |||||||
| Cash, cash equivalents and marketable securities | $ | 7,691,726 | $ | 2,570,590 | |||
| Accounts receivable, net | 2,850,367 | 2,100,286 | |||||
| Inventories | 1,909,584 | 2,055,788 | |||||
| Property, plant and equipment, net | 1,509,796 | 1,166,181 | |||||
| Intangible assets, net | 11,306,547 | 11,900,106 | |||||
| Goodwill | 1,171,561 | 1,169,023 | |||||
| Other assets | 2,404,812 | 1,534,811 | |||||
| Total assets | $ | 28,844,393 | $ | 22,496,785 | |||
| Current liabilities | $ | 6,054,952 | $ | 6,325,421 | |||
| Long-term liabilities | 8,898,449 | 4,363,032 | |||||
| Equity component of currently redeemable convertible notes | 27,382 | 63,831 | |||||
| Stockholders’ equity(2) | 13,863,610 | 11,744,501 | |||||
| Total liabilities and stockholders’ equity | $ | 28,844,393 | $ | 22,496,785 | |||
|
(1) Derived from the audited consolidated financial statements as of December 31, 2013. |
|||||||
|
(2) As of September 30, 2014, there were 1,513,593 shares of common stock issued and outstanding. |
|||||||
|
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in thousands) |
|||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2014 | 2013 | 2014 | 2013 | ||||||||||||
| Antiviral products: | |||||||||||||||
| Sovaldi – U.S. | $ | 2,199,519 | $ | — | $ | 7,328,817 | $ | — | |||||||
| Sovaldi – Europe | 523,455 | — | 1,087,364 | — | |||||||||||
| Sovaldi – Other International | 73,119 | — | 134,587 | — | |||||||||||
| 2,796,093 | — | 8,550,768 | — | ||||||||||||
| Atripla – U.S. | 621,088 | 575,533 | 1,689,366 | 1,740,689 | |||||||||||
| Atripla – Europe | 222,723 | 256,853 | 693,559 | 805,848 | |||||||||||
| Atripla – Other International | 50,976 | 67,283 | 162,164 | 168,313 | |||||||||||
| 894,787 | 899,669 | 2,545,089 | 2,714,850 | ||||||||||||
| Truvada – U.S. | 471,162 | 430,173 | 1,238,514 | 1,153,575 | |||||||||||
| Truvada – Europe | 326,345 | 313,963 | 987,512 | 970,982 | |||||||||||
| Truvada – Other International | 77,947 | 69,516 | 215,738 | 197,116 | |||||||||||
| 875,454 | 813,652 | 2,441,764 | 2,321,673 | ||||||||||||
| Complera / Eviplera – U.S. | 183,061 | 126,888 | 467,333 | 350,372 | |||||||||||
| Complera / Eviplera – Europe | 134,311 | 74,025 | 375,437 | 172,288 | |||||||||||
| Complera / Eviplera – Other International | 12,891 | 9,823 | 37,690 | 24,948 | |||||||||||
| 330,263 | 210,736 | 880,460 | 547,608 | ||||||||||||
| Stribild – U.S. | 278,840 | 134,700 | 695,347 | 323,639 | |||||||||||
| Stribild – Europe | 38,343 | 7,911 | 93,281 | 9,759 | |||||||||||
| Stribild – Other International | 10,852 | 1,342 | 24,198 | 2,097 | |||||||||||
| 328,035 | 143,953 | 812,826 | 335,495 | ||||||||||||
| Viread – U.S. | 122,654 | 108,718 | 320,261 | 305,311 | |||||||||||
| Viread – Europe | 87,177 | 86,177 | 258,833 | 262,425 | |||||||||||
| Viread – Other International | 65,806 | 36,660 | 167,902 | 124,339 | |||||||||||
| 275,637 | 231,555 | 746,996 | 692,075 | ||||||||||||
| Harvoni – Europe | 19,966 | — | 20,405 | — | |||||||||||
| 19,966 | — | 20,405 | — | ||||||||||||
| Other Antiviral – U.S. | 13,634 | 13,706 | 34,125 | 47,116 | |||||||||||
| Other Antiviral – Europe | 9,027 | 11,320 | 27,333 | 35,146 | |||||||||||
| Other Antiviral – Other International | 1,617 | 2,136 | 5,388 | 7,381 | |||||||||||
| 24,278 | 27,162 | 66,846 | 89,643 | ||||||||||||
| Total antiviral products – U.S. | 3,889,958 | 1,389,718 | 11,773,763 | 3,920,702 | |||||||||||
| Total antiviral products – Europe | 1,361,347 | 750,249 | 3,543,724 | 2,256,448 | |||||||||||
| Total antiviral products – Other International | 293,208 | 186,760 | 747,667 | 524,194 | |||||||||||
| 5,544,513 | 2,326,727 | 16,065,154 | 6,701,344 | ||||||||||||
| Letairis | 146,415 | 135,072 | 414,016 | 381,436 | |||||||||||
| Ranexa | 132,510 | 115,815 | 366,084 | 318,698 | |||||||||||
| AmBisome | 98,108 | 97,812 | 284,995 | 258,224 | |||||||||||
| Zydelig | 5,862 | — | 5,862 | — | |||||||||||
| Other products | 40,800 | 34,226 | 116,008 | 100,803 | |||||||||||
| 423,695 | 382,925 | 1,186,965 | 1,059,161 | ||||||||||||
| Total product sales | $ | 5,968,208 | $ | 2,709,652 | $ | 17,252,119 | $ | 7,760,505 | |||||||
Source:
Gilead Sciences, Inc.
Investors
Robin
Washington, 650-522-5688
Patrick O'Brien, 650-522-1936
or
Media
Amy
Flood, 650-522-5643